Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial |
| |
| Authors: | Henrik Watz Kay Tetzlaff Helgo Magnussen Achim Mueller Roberto Rodriguez-Roisin Emiel F M Wouters Claus Vogelmeier Peter M A Calverley |
| |
| Institution: | 1.Pulmonary Research Institute at Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN),German Center for Lung Research (DZL),Grosshansdorf,Germany;2.Boehringer Ingelheim International GmbH,Ingelheim am Rhein,Germany;3.Department of Sports Medicine,University of Tübingen,Tübingen,Germany;4.Boehringer Ingelheim Pharma GmbH & Co. KG,Biberach an der Riss,Germany;5.Hospital Clínic IDIBAPS-CIBERES,Universitat de Barcelona,Barcelona,Spain;6.Department of Respiratory Medicine,Maastricht University Medical Center,Maastricht,Netherlands;7.Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg,Philipps-Universit?t Marburg, Member of the German Center for Lung Research (DZL),Marburg,Germany;8.Institute of Ageing and Chronic Disease, Clinical Science Centre,University Hospital Aintree,Liverpool,UK |
| |
| Abstract: | BackgroundExacerbations of chronic obstructive pulmonary disease (COPD) are associated with loss of lung function and poor outcomes for patients. However, there are limited data on the time course of changes in forced expiratory volume in 1?s (FEV1) preceding the first reported symptom and after the start of an exacerbation.MethodsWISDOM was a multinational, randomized, double-blind, active-controlled, 52-week study in patients with severe-to-very severe COPD. Patients received triple therapy (long-acting muscarinic antagonist and long-acting β2-agonist/inhaled corticosteroid ICS]) for 6?weeks, and were randomized to continue triple therapy or stepwise withdrawal of the ICS (dual bronchodilator group). After suitable training, patients performed daily spirometry at home using a portable, battery-operated spirometer. In the present post hoc analysis, patients who continued to perform daily home spirometry and completed at least one measurement per week for a 56-day period before and after the start of a moderate or severe exacerbation were included. Missing values were imputed by linear interpolation (intermittent), backfilling (beginning) or carry forward (end). Exacerbation onset was the first day of a reported symptom of exacerbation.ResultsEight hundred and eighty-eight patients in the WISDOM study had a moderate/severe exacerbation after the complete ICS withdrawal visit; 360 of them contributed at least one FEV1 measure per week for the 8?weeks before and after the event and are included in this analysis.Mean daily FEV1 began to decline from approximately 2?weeks before the onset of symptoms of an exacerbation, dropping from 0.907?L (mean Days ??56 to ??36 before the exacerbation) to 0.860?L on the first day of the exacerbation. After the exacerbation, mean FEV1 improved but did not return to pre-exacerbation levels (mean Days 36–56 after the exacerbation, 0.875?L).The pattern of FEV1 changes around exacerbations was similar in the triple therapy and dual bronchodilator groups, and a similar pattern was seen in moderate and severe exacerbations when analysed separately.ConclusionsMean lung function starts to decline prior to the first reported symptoms of an exacerbation, and does not recover to pre-exacerbation levels 8?weeks after the event.Trial registrationWISDOM (ClinicalTrials.gov number, NCT00975195). |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
